Danaher Corporation has entered a definitive agreement to acquire Masimo Corporation for $9.9 billion, with the purchase price set at $180 per share. The acquisition is a strategic move to enhance Danaher's presence in the medical technology sector, anticipated to drive high-single-digit core revenue growth for Masimo. This comes on the heels of Danaher's strong financial performance in 2025, where it reported $24.6 billion in revenue and $3.6 billion in net income, alongside an adjustment in its 2026 earnings forecast. Despite facing a challenging stock trend, Danaher aims to finance this acquisition partly through new senior notes valued at €2.98 billion.
Loading timeline…